Adage Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Adage Capital Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,101,611	Closed	-$11.7M	–	1052
2022 Q2	$11.7M	Buy	+1,101,611	New	+$11.4M	0.03%	634
2021 Q2	–	Sell	-1,800,000	Closed	-$18.3M	–	1019
2021 Q1	$18.3M	Buy	1,800,000 +200,000	+13%	+$2.06M	0.04%	489
2020 Q4	$11.9M	Buy	+1,600,000	New	+$8.25M	0.03%	548
2020 Q2	–	Sell	-7,500,000	Closed	-$15M	–	733
2020 Q1	$15M	Buy	7,500,000 +3,500,000	+88%	+$9.64M	0.04%	386
2019 Q4	$13.8M	Buy	+4,000,000	New	+$10.1M	0.03%	478

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Adage Capital Partners's BCRX Position: Q3 2022 in Review

Adage Capital Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 1,101,611 shares — an estimated $11.7M sold.

Adage Capital Partners first reported a position in BCRX in Q4 2019 and held it in 5 quarters. The position peaked at $18.3M in Q1 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

Adage Capital Partners reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Adage Capital Partners sold 1,101,611 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $11.7M.
Adage Capital Partners first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 5 quarters.
Adage Capital Partners's BioCryst Pharmaceuticals position peaked at $18.3M in Q1 2021.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Adage Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.